Advertisement

Topics

Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischaemic optic neuropathy.

06:00 EST 25th January 2011 | BioPortfolio

Summary of "Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischaemic optic neuropathy."

Background:  The aim was to evaluate the effect of a single intravitreal ranibizumab injection in eyes with non-arteritic anterior ischaemic optic neuropathy. Methods:  Four eyes of four patients comprised the study group. In addition to a standard ocular examination, visual field testing and retinal nerve fibre layer thickness analysis were performed prior to injection and one and three months after the injection. Results:  Mean time between visual loss and the intravitreal injection was 7.8 days (range, 2-15 days). The mean age of patients was 58.2 years (range, 45-63 years). After a single dose of ranibizumab injection, all patients experienced a visual gain. Mean visual acuity (VA) was 1.15 ± 0.26 logMar before the injection and improved to 0.37 ± 0.09 logMar at the third post-injection month. The mean retinal nerve fibre layer thickness measured with spectral domain optical coherence tomography significantly decreased after the injection in all eyes. No complication related to the injections was observed during the following three months. Conclusion:  Intravitreal ranibizumab injection may be a treatment option in eyes with non-arteritic anterior ischaemic optic neuropathy and a short disease history.

Affiliation

Dokuz Eylul University, Department of Ophthalmology, Izmir, Turkey E-mail: osman.saatci@deu.edu.tr.

Journal Details

This article was published in the following journal.

Name: Clinical & experimental optometry : journal of the Australian Optometrical Association
ISSN: 1444-0938
Pages:

Links

DeepDyve research library

PubMed Articles [17231 Associated PubMed Articles listed on BioPortfolio]

Placenta Growth Factor in Eyes with Neovascular Glaucoma Is Decreased after Intravitreal Ranibizumab Injection.

To evaluate changes in the concentrations of placental growth factor (PlGF) and vascular endothelial growth factor-A (VEGF-A) in aqueous humor of patients with neovascular glaucoma (NVG) before and af...

ACUTE MACULAR NEURORETINOPATHY AFTER RANIBIZUMAB INJECTION IN A DIABETIC PATIENT.

To report a case of acute macular neuroretinopathy occurring after intravitreal ranibizumab injection for diabetic macular edema.

Comparison of the Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema in Vitrectomized and Nonvitrectomized Eyes.

To compare the effectiveness of intravitreal ranibizumab (IVR) for diabetic macular edema (DME) between eyes with and without previous vitrectomy.

Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study.

The purpose of this study is to make a prospective evaluation of the effect of timolol 0.1% eye gel on short-term intraocular pressure (IOP) after an intravitreal injection (IVI) of ranibizumab.

VISUAL ACUITY OUTCOMES OF RANIBIZUMAB TREATMENT IN PATHOLOGIC MYOPIC EYES WITH MACULAR RETINOSCHISIS AND CHOROIDAL NEOVASCULARIZATION.

To investigate visual and morphological outcome in eyes with MRS and choroidal neovascularization (CNV) secondary to pathologic myopia treated with intravitreal (IVT) ranibizumab.

Clinical Trials [7551 Associated Clinical Trials listed on BioPortfolio]

Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study

Title of study: Effects of Ranibizumab to delay or regression non-proliferative diabetic retinopathy(NPDR) with DME assessed by microaneurysm changes: A pilot study Objectives To evaluate...

Intravitreal Ranibizumab For Persistent New Vessels In Diabetic Retinopathy(Inipe Study)

To evaluate the fluorescein angiographic and visual acuity effects of a single intravitreal injection of ranibizumab for the management of persistent new vessels associated with diabetic r...

Intravitreal Ranibizumab for VH Due to PDR (N)

This study is being conducted to determine if intravitreal injections of ranibizumab decrease the proportion of eyes in which vitrectomy is performed compared with saline injections in eye...

Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.

This open-label, Phase IV prospective, observational study will evaluate patients, who have been diagnosed with Neovascular Age-Related Macular Degeneration and have previously received ei...

Intravitreal Injection of Ranibizumab Versus Sham Before Vitrectomy in Patients With Proliferative Diabetic Retinopathy

Certain percent of the eyes with proliferative diabetic retinopathymay require pars plana vitrectomy (PPV) due to vitreous haemorrhage, proliferative membrane, and tractional retinal detac...

Medical and Biotech [MESH] Definitions

Hemorrhagic necrosis that was first demonstrated in rabbits with a two-step reaction, an initial local (intradermal) or general (intravenous) injection of a priming endotoxin (ENDOTOXINS) followed by a second intravenous endotoxin injection (provoking agent) 24 h later. The acute inflammation damages the small blood vessels. The following intravascular coagulation leads to capillary and venous THROMBOSIS and NECROSIS. Shwartzman phenomenon can also occur in other species with a single injection of a provoking agent, and during infections or pregnancy. Its susceptibility depends on the status of IMMUNE SYSTEM, coagulation, FIBRINOLYSIS, and blood flow.

The administration of substances into the VITREOUS BODY of the eye with a hypodermic syringe.

Acute conjunctival inflammation in the newborn, usually caused by maternal gonococcal infection. The causative agent is NEISSERIA GONORRHOEAE. The baby's eyes are contaminated during passage through the birth canal.

Gases that irritate the eyes, throat, or skin. Severe lacrimation develops upon irritation of the eyes.

Partial or complete loss of vision in one half of the visual field(s) of one or both eyes. Subtypes include altitudinal hemianopsia, characterized by a visual defect above or below the horizontal meridian of the visual field. Homonymous hemianopsia refers to a visual defect that affects both eyes equally, and occurs either to the left or right of the midline of the visual field. Binasal hemianopsia consists of loss of vision in the nasal hemifields of both eyes. Bitemporal hemianopsia is the bilateral loss of vision in the temporal fields. Quadrantanopsia refers to loss of vision in one quarter of the visual field in one or both eyes.

Quick Search
Advertisement
 


DeepDyve research library

Relevant Topic

Ophthalmology
Ophthalmology is the branch of medicine that is devoted to the study and treatment of eye diseases. As well as mild visual defects correctable by lenses, ophthalmology is concerned with glaucoma, uveitis and other serious conditions affecting the eye, ...


Searches Linking to this Article